Vident Advisory, LLC Neurocrine Biosciences Inc Transaction History
Vident Advisory, LLC
- $4.8 Trillion
- Q1 2024
A detailed history of Vident Advisory, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vident Advisory, LLC holds 97,754 shares of NBIX stock, worth $13.6 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
97,754
Previous 2,535
3756.17%
Holding current value
$13.6 Million
Previous $334 Million
3936.4%
% of portfolio
0.28%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding NBIX
# of Institutions
628Shares Held
94.4MCall Options Held
505KPut Options Held
343K-
Black Rock Inc. New York, NY13.8MShares$1.91 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.93MShares$1.38 Billion0.03% of portfolio
-
State Street Corp Boston, MA3.99MShares$555 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.3MShares$319 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.25MShares$313 Million0.49% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...